Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Treatment of hepatitis C"'
Autor:
Banerjee, D.1, Reddy, K. R.1
Publikováno v:
Alimentary Pharmacology & Therapeutics. Mar2016, Vol. 43 Issue 6, p674-696. 23p.
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 97, Iss 12, Pp 860-869 (2005)
Objective: to evaluate the evolution of histological changes observed in patients with chronic hepatitis C (CHC) and sustained response (SR) compared to non-responders (NR) to antiviral treatment. Methods: a retrospective study was performed in a tot
Externí odkaz:
https://doaj.org/article/ffe5843be26b4baf92d99c3df9e91d3c
Autor:
Andrew Fraser, Eleanor Barnes, Alan Yeung, Sharon J. Hutchinson, Stephen T. Barclay, Indra Neil Guha, Jennifer Benselin, Philip J. Johnson, Peter Uhd Jepsen, Victoria Hamill, Andrew Bathgate, William L. Irving, April Went, Hamish Innes, David J. Goldberg, Peter C. Hayes, M. Azim Ansari, Scott A. McDonald, John F. Dillon
Publikováno v:
Innes, H, Jepsen, P, McDonald, S, Dillon, J, Hamill, V, Yeung, A, Benselin, J, Went, A, Fraser, A, Bathgate, A, Ansari, M A, Barclay, S T, Goldberg, D, Hayes, P C, Johnson, P, Barnes, E, Irving, W, Hutchinson, S & Guha, I N 2021, ' Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection ', JHEP Reports, vol. 3, no. 6, 100384 . https://doi.org/10.1016/j.jhepr.2021.100384
JHEP REPORTS
JHEP Reports
JHEP Reports, Vol 3, Iss 6, Pp 100384-(2021)
JHEP REPORTS
JHEP Reports
JHEP Reports, Vol 3, Iss 6, Pp 100384-(2021)
Background & Aims Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis
Publikováno v:
PLoS ONE; 2010, Vol. 5 Issue 8, p1-10, 10p, 6 Graphs
Introduction: Hepatitis C is an RNA flavivirus that infects 4 million people in the United States making up approximately 1.8% of the population, and 150-200 million worldwide. In persons with HIV, its prevalence is estimated to be approximately 50%.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::816c6dad8c3467e77ea4f283aae7080f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Karunrat Tewthanom
Thai Bulletin of Pharmaceutical Science (TBPS), 12, 1 (January-June)2017
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2d2c31eaf44e87bd8e5bc5f4c8b07b2
Publikováno v:
Journal of Microbiology and Infectious Diseases, Vol 2, Iss 3, Pp 100-108 (2012)
Volume: 2, Issue: 03 100-108
Journal of Microbiology and Infectious Diseases
Volume: 2, Issue: 03 100-108
Journal of Microbiology and Infectious Diseases
Amaç: Kronik hepatit C tedavisi için günümüzde pegile interferon alfa (peg-IFN) ve ribavirin tedavisi önerilmektedir. Tedavide amaç kalıcı viral yanıt (KVY) elde etmektir. Gereç ve yöntem: Bu çalışmaya Kronik hepatit C tanısıyla teda
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Evangelista Sagnelli, Massimo Fasano, Caterina Sagnelli, Teresa Santantonio, Nicola Coppola, Mariantonietta Pisaturo
Introduction: Acute hepatitis C (AHC) is asymptomatic in about 70-80 % of cases and, therefore, is usually undiagnosed. Although the clinical course is typically mild, AHC has a high rate of transition to chronicity. Material and methods: We evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7353d6a25837207ca0b8997a30cc801
http://hdl.handle.net/11591/182117
http://hdl.handle.net/11591/182117